Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Predictors of breastfeeding non-initiation in the NICU.

Gertz B, DeFranco E.

Matern Child Nutr. 2019 Jul;15(3):e12797. doi: 10.1111/mcn.12797. Epub 2019 Apr 2.

PMID:
30767426
2.

Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap® (XM17), Comparability with Gonal-f®, and Performance/Consistency.

Winstel R, Wieland J, Gertz B, Mueller A, Allgaier H.

Drugs R D. 2017 Jun;17(2):305-312. doi: 10.1007/s40268-017-0182-z.

3.

[Paediatric palliative care (PPC) - a particular challenge : Tasks, aims and specifics].

Zernikow B, Gertz B, Hasan C.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Jan;60(1):76-81. doi: 10.1007/s00103-016-2479-4. German.

PMID:
27878604
4.
5.

Mitochondrial DNMT3A and DNA methylation in skeletal muscle and CNS of transgenic mouse models of ALS.

Wong M, Gertz B, Chestnut BA, Martin LJ.

Front Cell Neurosci. 2013 Dec 25;7:279. doi: 10.3389/fncel.2013.00279. eCollection 2013.

6.

Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta.

Gertz B, Kes P, Essaian A, Bias P, Buchner A, Zellner D.

Curr Med Res Opin. 2012 Jul;28(7):1101-10. doi: 10.1185/03007995.2012.688736. Epub 2012 May 23.

PMID:
22533679
7.
8.

Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial.

Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A.

Arch Drug Inf. 2011 Sep;4(3):33-41.

9.

Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial.

Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A.

Arch Drug Inf. 2010 Sep;3(3):45-53.

10.

Epoetin theta: efficacy and safety of IV administration in anaemic haemodialysis patients in the maintenance phase in comparison to epoetin beta.

Gertz B, Kohler E, Kes P, Essaian A, Bias P, Buchner A, Elsässer R.

Curr Med Res Opin. 2010 Oct;26(10):2393-402. doi: 10.1185/03007995.2010.511084.

PMID:
20812790
11.

Diffusion tensor imaging detects areas of abnormal white matter microstructure in patients with partial ornithine transcarbamylase deficiency.

Gropman AL, Gertz B, Shattuck K, Kahn IL, Seltzer R, Krivitsky L, Van Meter J.

AJNR Am J Neuroradiol. 2010 Oct;31(9):1719-23. doi: 10.3174/ajnr.A2122. Epub 2010 May 20.

12.

The mitochondrial permeability transition pore in motor neurons: involvement in the pathobiology of ALS mice.

Martin LJ, Gertz B, Pan Y, Price AC, Molkentin JD, Chang Q.

Exp Neurol. 2009 Aug;218(2):333-46. doi: 10.1016/j.expneurol.2009.02.015. Epub 2009 Mar 9.

13.

Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet.

Schwartz JI, Thach C, Lasseter KC, Miller J, Hreniuk D, Hilliard DA, Snyder KM, Gertz BJ, Gottesdiener KM.

J Clin Pharmacol. 2007 Dec;47(12):1521-31. Epub 2007 Oct 9.

PMID:
17925592
14.

Pharmacokinetic evaluation of rofecoxib : comparison of tablet and suspension formulations.

Schwartz JI, Larson PJ, Porras AG, Viswanathan-Aiyer KJ, Agrawal NG, Lasseter KC, Mazenko RS, Merschman SA, Gertz BJ.

Clin Drug Investig. 2003;23(8):503-9.

PMID:
17535062
15.

Regulation of muscle growth by multiple ligands signaling through activin type II receptors.

Lee SJ, Reed LA, Davies MV, Girgenrath S, Goad ME, Tomkinson KN, Wright JF, Barker C, Ehrmantraut G, Holmstrom J, Trowell B, Gertz B, Jiang MS, Sebald SM, Matzuk M, Li E, Liang LF, Quattlebaum E, Stotish RL, Wolfman NM.

Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18117-22. Epub 2005 Dec 5.

16.

Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis.

Gineyts E, Mo JA, Ko A, Henriksen DB, Curtis SP, Gertz BJ, Garnero P, Delmas PD.

Ann Rheum Dis. 2004 Jul;63(7):857-61.

17.

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.

Weir MR, Sperling RS, Reicin A, Gertz BJ.

Am Heart J. 2003 Oct;146(4):591-604. Review.

PMID:
14564311
18.

Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials.

Katz N, Ju WD, Krupa DA, Sperling RS, Bozalis Rodgers D, Gertz BJ, Gimbel J, Coleman S, Fisher C, Nabizadeh S, Borenstein D; Vioxx Chronic Low Back Pain Study Group.

Spine (Phila Pa 1976). 2003 May 1;28(9):851-8; discussion 859.

PMID:
12941996
19.

Effects of renal insufficiency and hemodialysis on the pharmacokinetics of rofecoxib.

Gottesdiener K, Agrawal N, Porras A, Wong P, Rogers JD, Gertz BJ, Redfern JS, Marbury T.

Am J Ther. 2003 Jul-Aug;10(4):252-8.

PMID:
12845388
20.

Characterization of etoricoxib, a novel, selective COX-2 inhibitor.

Dallob A, Hawkey CJ, Greenberg H, Wight N, De Schepper P, Waldman S, Wong P, DeTora L, Gertz B, Agrawal N, Wagner J, Gottesdiener K.

J Clin Pharmacol. 2003 Jun;43(6):573-85.

PMID:
12817520
21.

Pharmacokinetics of alendronate: an overview.

Lin JH, Russell G, Gertz B.

Int J Clin Pract Suppl. 1999 Apr;101:18-26.

PMID:
12669737
22.

Effect of rofecoxib on prednisolone and prednisone pharmacokinetics in healthy subjects.

Schwartz JI, Mukhopadhyay S, Porras AG, Viswanathan-Aiyer KJ, Adcock S, Ebel DL, Gertz BJ.

J Clin Pharmacol. 2003 Feb;43(2):187-92.

PMID:
12616672
23.

Human dendritic cells express functional formyl peptide receptor-like-2 (FPRL2) throughout maturation.

Yang D, Chen Q, Gertz B, He R, Phulsuksombati M, Ye RD, Oppenheim JJ.

J Leukoc Biol. 2002 Sep;72(3):598-607.

PMID:
12223529
24.

Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.

Gottesdiener K, Schnitzer T, Fisher C, Bockow B, Markenson J, Ko A, DeTora L, Curtis S, Geissler L, Gertz BJ; Protocol 007 Study Group.

Rheumatology (Oxford). 2002 Sep;41(9):1052-61. Erratum in: Rheumatology (Oxford). 2003 Jun;42(6):814.

PMID:
12209041
25.

A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.

Matsumoto AK, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PL, Lines CR, Gertz BJ, Curtis S; Etoricoxib Rheumatoid Arthritis Study Group.

J Rheumatol. 2002 Aug;29(8):1623-30.

PMID:
12180720
26.
27.

Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.

Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, Gertz BJ, Gottesdiener KM, Laurenzi M, Redfern KJ, Brune K.

Clin Pharmacol Ther. 2002 Jul;72(1):50-61.

PMID:
12152004
28.

Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.

Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, De Smet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ.

Cancer. 2002 Jun 1;94(11):3032-41.

29.

A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].

Collantes E, Curtis SP, Lee KW, Casas N, McCarthy T, Melian A, Zhao PL, Rodgers DB, McCormick CL, Lee M, Lines CR, Gertz BJ; Etoricoxib Rheumatoid Arthritis Study Group.

BMC Fam Pract. 2002 May 22;3:10.

30.
31.
32.

Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization.

Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, Moller DE.

Endocrinology. 2002 Mar;143(3):998-1007.

PMID:
11861525
33.

Effect of rofecoxib on the pharmacokinetics of chronically administered oral contraceptives in healthy female volunteers.

Schwartz JI, Wong PH, Porras AG, Ebel DL, Hunt TR, Gertz BJ.

J Clin Pharmacol. 2002 Feb;42(2):215-21.

PMID:
11831545
34.

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.

Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ.

Circulation. 2001 Nov 6;104(19):2280-8.

PMID:
11696466
35.

Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients.

Schwartz JI, Agrawal NG, Wong PH, Bachmann KA, Porras AG, Miller JL, Ebel DL, Sack MR, Holmes GB, Redfern JS, Gertz BJ.

J Clin Pharmacol. 2001 Oct;41(10):1120-30.

PMID:
11583481
36.

Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.

Codner E, Cassorla F, Tiulpakov AN, Mericq MV, Avila A, Pescovitz OH, Svensson J, Cerchio K, Krupa D, Gertz BJ, Murphy G.

Clin Pharmacol Ther. 2001 Jul;70(1):91-8.

PMID:
11452249
37.

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.

Cocquyt V, Van Belle S, Reinhardt RR, Decramer ML, O'Brien M, Schellens JH, Borms M, Verbeke L, Van Aelst F, De Smet M, Carides AD, Eldridge K, Gertz BJ.

Eur J Cancer. 2001 May;37(7):835-42.

PMID:
11313170
38.

Renal effects of COX-2-selective inhibitors.

Brater DC, Harris C, Redfern JS, Gertz BJ.

Am J Nephrol. 2001 Jan-Feb;21(1):1-15. Review.

PMID:
11275626
39.

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.

Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ.

J Clin Oncol. 2001 Mar 15;19(6):1759-67.

PMID:
11251007
40.

Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.

Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ; MK-677/Alendronate Study Group.

J Clin Endocrinol Metab. 2001 Mar;86(3):1116-25.

PMID:
11238495
41.

Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production.

Wight NJ, Gottesdiener K, Garlick NM, Atherton CT, Novak S, Gertz BJ, Calder NA, Cote J, Wong P, Dallob A, Hawkey CJ.

Gastroenterology. 2001 Mar;120(4):867-73.

PMID:
11231941
42.

The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.

Schwartz JI, Bugianesi KJ, Ebel DL, De Smet M, Haesen R, Larson PJ, Ko A, Verbesselt R, Hunt TL, Lins R, Lens S, Porras AG, Dieck J, Keymeulen B, Gertz BJ.

Clin Pharmacol Ther. 2000 Dec;68(6):626-36.

PMID:
11180023
43.

Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.

Schwartz JI, De Smet M, Larson PJ, Verbesselt R, Ebel DL, Lins R, Lens S, Porras AG, Gertz BJ.

J Clin Pharmacol. 2001 Jan;41(1):107-12.

PMID:
11144988
44.

Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.

Van Hecken A, Schwartz JI, Depré M, De Lepeleire I, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL, Gertz BJ, De Schepper PJ.

J Clin Pharmacol. 2000 Oct;40(10):1109-20.

PMID:
11028250
45.

Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.

Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, Pinto MB, Dilzer SC, Obrda O, Sundblad KJ, Gumbs CP, Ebel DL, Quan H, Larson PJ, Schwartz JI, Musliner TA, Gertz BJ, Brater DC, Yao SL.

Ann Intern Med. 2000 Jul 4;133(1):1-9.

PMID:
10877734
46.

Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans.

Depré M, Ehrich E, Van Hecken A, De Lepeleire I, Dallob A, Wong P, Porras A, Gertz BJ, De Schepper PJ.

Eur J Clin Pharmacol. 2000 May;56(2):167-74.

PMID:
10877012
47.

Single dose methodology to assess the influence of an alpha1-adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia.

Curtis SP, Eardley I, Boyce M, Larson P, Haesen R, Gottesdiener K, Gertz BJ.

Br J Clin Pharmacol. 2000 Mar;49(3):269-73.

48.

Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity.

McCrea J, Prueksaritanont T, Gertz BJ, Carides A, Gillen L, Antonello S, Brucker MJ, Miller-Stein C, Osborne B, Waldman S.

J Clin Pharmacol. 1999 Dec;39(12):1212-20.

PMID:
10586386
49.

Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.

Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman M, Zeng Q, Morrison B, Bolognese J, Seidenberg B, Gertz BJ.

J Rheumatol. 1999 Nov;26(11):2438-47.

PMID:
10555907
50.

Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man.

Newby DE, Sciberras DG, Ferro CJ, Gertz BJ, Sommerville D, Majumdar A, Lowry RC, Webb DJ.

Br J Clin Pharmacol. 1999 Sep;48(3):336-44.

Supplemental Content

Support Center